Jolkinolide B inhibits proliferation or migration and promotes apoptosis of MCF-7 or BT-474 breast cancer cells by downregulating the PI3K-Akt pathway
| Autor: | Lei Liu, Na Liu, Xiaodong Zhang, Lei Shen, Yang Wang, Bing-Hua Liu, Dan-Yang Liu, Shi-Yang Shen |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Down-Regulation
Antineoplastic Agents Apoptosis Breast Neoplasms Phosphatidylinositol 3-Kinases Breast cancer Cell Movement Euphorbia Drug Discovery medicine Humans Protein kinase B PI3K/AKT/mTOR pathway Cell Proliferation Pharmacology Cell growth Chemistry Computational Biology Cancer medicine.disease In vitro Oncogene Protein v-akt Treatment Outcome MCF-7 MCF-7 Cells Cancer research Diterpenes Drugs Chinese Herbal Signal Transduction |
| Zdroj: | Journal of Ethnopharmacology. 282:114581 |
| ISSN: | 0378-8741 |
| DOI: | 10.1016/j.jep.2021.114581 |
| Popis: | ETHNOPHARMACOLOGICAL RELEVANCE The diterpenoids extracted from Euphorbia kansui S.L. Liou ex S.B.Ho, Euphorbia fischeriana Steud. have good antitumor effects. Jolkinolide B has anti-breast cancer effect, but it is unclear whether it has different therapeutic effects between luminal A subtype and luminal B subtype breast cancer. AIM OF THE STUDY This study investigated the Jolkinolide B has different therapeutic, important targets and pathways effects between luminal A subtype and luminal B subtype breast cancer. MATERIALS AND METHODS We used bioinformatics to predict the biological process and molecular mechanism of Jolkinolide B in treating two types of breast cancer. Then, in vitro, cultured MCF-7 cells and BT-474 cells were divided into control group, PI3K inhibitor + control group, Jolkinolide B group and PI3K inhibitor + Jolkinolide B group. The CCK-8 assay, Flow cytometric analysis and Transwell cell migration assay was used to detect the cell proliferation, apoptosis, and migration in each group, respectively. ELISA was used to measure the content of Akt and phosphorylated Akt (p-Akt) in cell lysis buffer. RESULTS Compared to luminal A breast cancer, Jolkinolide B had more targets, proliferation, migration processes and KEGG pathways when treating luminal B subtype breast cancer. Jolkinolide B significantly prolonged the survival time of luminal B subtype breast cancer patients. Compared to the control group, the cell proliferation absorbance value (A value) and migration number of the two kinds of breast cancer cells in the Jolkinolide B group were decreased (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect